[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592951":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":21,"responsibleParty":61,"collaborators":63,"id":66,"slug":7,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":7,"studyType":79,"phases":7,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Anifrolumab","Anifrolumab prescribed per local practice",[14],"Saphnelo",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[22,34,43,52],{"facility":23,"status":24,"city":25,"state":7,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":7},"Research Site","RECRUITING","Copenhagen","23000","Denmark",{"type":29,"coordinates":30},"Point",[31,32],12.56553,55.67594,{"lat":32,"lon":31},{"facility":23,"status":24,"city":35,"state":7,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":42,"contacts":7},"Charenton-le-Pont","94220","France",{"type":29,"coordinates":39},[40,41],2.41217,48.82209,{"lat":41,"lon":40},{"facility":23,"status":24,"city":44,"state":7,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":51,"contacts":7},"Essen","45128","Germany",{"type":29,"coordinates":48},[49,50],7.01228,51.45657,{"lat":50,"lon":49},{"facility":23,"status":24,"city":53,"state":7,"zip":54,"country":55,"cosmosGeoPoint":56,"geoPoint":60,"contacts":7},"Barcelona","08007","Spain",{"type":29,"coordinates":57},[58,59],2.15899,41.38879,{"lat":59,"lon":58},{"type":62,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[64],{"name":65,"class":6},"IQVIA Pty Ltd","100592951",false,"NCT07000110","Anifrolumab Malignancy and Serious Infections Study","A Non-Interventional Multi-Country Post-Authorisation Safety Study (PASS) to Assess the Incidence of Serious Infections & Malignancies in Systemic Lupus Erythematosus (SLE) Patients Exposed to Anifrolumab","SIMA","Inclusion Criteria:\n\n* First prescription of anifrolumab in the study period (no anifrolumab prescription prior to index date): date of first anifrolumab prescription will be the index date\n* A minimum data availability of 12 months prior to index date\n* Age ≥18 years at index date\n* SLE severity: patients with moderate to severe SLE at index date\n* SLE activity: patients with at least a flare (uncontrolled SLE) in the 6 months prior to index date\n\nExclusion Criteria:\n\n* A diagnosis of any malignancy prior to index date\n* A diagnosis of HIV\u002FAIDS or congenital immunodeficiency prior to index date\n* Organ or bone marrow transplant procedure prior to index date\n* A diagnosis of serious infection in the previous 6 months","ALL","18 Years","130 Years",{"count":77,"type":78},3195,"ESTIMATED","OBSERVATIONAL","This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate\u002Fsevere SLE patients who receive anifrolumab compared with a comparable population of moderate\u002Fsevere SLE patients on standard of care who do not initiate anifrolumab.",[82],"Systemic Lupus Erythematosus",[84],"malignancies, infections, anifrolumab","2026-06-18",{"date":87,"type":88},"2026-06-22","ACTUAL",{"date":90,"type":88},"2026-01-26",{"date":92,"type":78},"2031-11-30",{"name":5,"class":6},4]